This FRα-specific mAb is currently in clinical use for the treatment of NSCLC and ovarian cancers (Konner et al., 2010; Shi et al., 2013; Ponte et al., 2016). This evidence concerns the gene FOLR1 and non-small cell lung carcinoma.